Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group

Authors:
  • INIon Niculescu-Duvaz
    Ion Niculescu-Duvaz
  • CGCatherine Gaulon
    Catherine Gaulon
  • HDHarmen P. Dijkstra
    Harmen P. Dijkstra
  • DNDan Niculescu-Duvaz
    Dan Niculescu-Duvaz
  • DMDelphine Ménard
    Delphine Ménard
  • ANArnaud Nourry
    Arnaud Nourry
  • HMHelen A. Manne
    Helen A. Manne
  • FFFrank Friedlos
    Frank Friedlos
  • LOLesley M. Ogilvie
    Lesley M. Ogilvie

Abstract
We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF), a kinase whose mutant form (V600E) is implicated in several types of cancer, with a particularly high frequency in melanoma. Our previously described inhibitors with a tripartite A−B−C system (where A is a hinge binding pyrido[4,5-b]imidazolone system, B is an aryl spacer group, and C is a heteroaromatic group) were potent against purified V600EBRAF in vitro but were less potent in accompanying cellular assays. Substitution of different aromatic heterocycles for the phenyl based C-ring is evaluated herein as a potential means of improving the cellular potencies of these inhibitors. Substituted pyrazoles, particularly 3-tert-butyl-1-aryl-1H-pyrazoles, increase the cellular potencies without detrimental effects on the potency on isolated V600EBRAF. Thus, compounds have been synthesized that inhibit, with low nanomolar concentrations, V600EBRAF, its downstream signaling in cells [as measured by the reduction of the phosphorylation of extracellular regulated kinase (ERK)], and the proliferation of mutant BRAF-dependent cells. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo.